drugset / Trial / NCT03100500

A Long-term Safety Study of QMF149 in Japanese Participants With Asthma

NCT03100500

Phase 3 Completed 51 enrolled Novartis Pharmaceuticals
NaSingle-groupOpen-labelTreatment

Summary

The purpose of this study was to provide long term safety data of QMF149 in Japanese participants with inadequately controlled asthma for the registration of QMF149 in Japan.

Timeline

Start
2017-04-25
Primary completion
2018-07-19
Completion
2019-02-12

Drugs

EvaluationDrugModalityDoseRoute
Subject Mometasone furoate Other / unclassified 150 ug Inhaled
Subject Mometasone furoate Other / unclassified 320 ug Inhaled

Indications